News for Healthier Living
New Study Reveals How Blood Cancers Outsmart BTK-Targeted Therapies
Researchers have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase (BTK) inhibitors and newer BTK degraders, a finding that could help shape the next generation of therapies for patients with chronic lymphocytic leukemia (CLL) and related malignancies.
July 27, 2026
August 1 2026July 31 2026July 30 2026July 29 2026July 28 2026July 27 2026July 26 2026July 25 2026July 24 2026July 23 2026July 22 2026July 21 2026July 20 2026
|
|
|
|
|